Cencora, INC 8-K filings

Cencora, Inc. has reaffirmed its fiscal year 2026 adjusted diluted EPS guidance of $17.75 to $17.95, indicating that a planned shift of certain Walgreens volume outside the company was fully anticipated and accounted for.

Cencora, Inc. has amended and restated its multi-currency revolving credit facility, increasing the aggregate commitment to $7.0 billion and extending the maturity date to July 2031.

Cencora announced robust third-quarter fiscal 2026 results, featuring a 5.1% year-over-year revenue increase to $84.8 billion and a 12.0% rise in adjusted diluted EPS to $4.48, leading to an upward revision of full-year EPS guidance.

Cencora, Inc. announced a leadership change in its Human Resources department, with Silvana Battaglia retiring and Samantha Hammock appointed as the new Executive Vice President and Chief Human Resources Officer.

Cencora has appointed former Bath & Body Works CFO Eva C. Boratto as its new Executive Vice President and Chief Financial Officer, effective June 29, 2026.

Cencora, Inc. announced robust fiscal 2026 second quarter results, with revenue up 3.8% year-over-year to $78.4 billion and adjusted diluted EPS increasing 7.5% to $4.75, leading to a raised full-year EPS outlook.

Cencora announced a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion, expanding its Retina Consultants of America network.

Cencora said CFO James F. Cleary will retire on June 30, 2026 and reaffirmed fiscal 2026 adjusted diluted EPS guidance of $17.45–$17.75.

Cencora, Inc. announced the results of its 2026 Annual Meeting of Shareholders, confirming the election of eleven directors, advisory approval of executive compensation, and ratification of Ernst & Young LLP as auditor.

Cencora, Inc. successfully closed a public offering of $3.0 billion in senior notes across five different series with varying interest rates and maturity dates.

Cencora, Inc. announced a strategic reorganization of its reporting segments and reported strong fiscal 2025 financial results, including a 9.3% revenue increase and 3.0% net income growth, despite significant goodwill impairment and increased interest expenses.

Cencora announced robust fiscal Q1 2026 results with revenue up 5.5% to $85.9 billion and raised its adjusted operating income guidance for the full fiscal year.

Cencora, Inc. announced the appointment of Ellen G. Cooper, Chairman, President, and CEO of Lincoln Financial, as a new independent director to its Board, effective January 20, 2026.

Cencora, Inc. has finalized new credit facilities totaling $4.5 billion to fund its OneOncology acquisition and increased its revolving credit facility to $5.5 billion, replacing prior bridge financing.

Cencora announced it will acquire the majority of OneOncology for approximately $5.0 billion, accelerating its specialty solutions offering and raising long-term guidance.

Cencora announced robust fiscal year 2025 results with significant revenue growth and increased adjusted diluted EPS, alongside a dividend hike and raised long-term guidance, despite a GAAP net loss in Q4.

Cencora, Inc. announced amendments to its term loan, shortening its maturity, and its money market facility, adjusting borrowing limits for seasonal liquidity.

Cencora, Inc. announced a $111.3 million settlement, to be paid by insurers, resolving a long-standing stockholder derivative action related to opioid distribution oversight.

Cencora, Inc. announced the appointment of D. Mark Durcan as Chairman of its Board of Directors, succeeding retiring Steven H. Collis, effective October 1, 2025.

Cencora, Inc. reported an 8.7% year-over-year revenue increase to $80.7 billion and raised its fiscal year 2025 adjusted diluted EPS guidance to $15.85-$16.00.

Cencora, Inc. has increased its receivables securitization facility to $1.5 billion and enhanced its accordion feature to $500 million, providing significant additional liquidity and funding for its ongoing business operations.

Cencora, Inc. has significantly enhanced its financial liquidity and extended its debt maturity profile by amending and restating its revolving credit facility to $4.5 billion and extending its maturity to June 2030, while also conforming terms of its term loan facility.

Cencora, Inc. announced the appointment of Lori J. Ryerkerk as an independent director, effective June 1, 2025, while also disclosing the immediate resignation of Ornella Barra due to Walgreens Boots Alliance, Inc.'s anticipated ownership reduction below 5%.

Cencora, Inc. completes the sale of €1 billion in senior notes due in 2028 and 2032 to refinance existing debt and for general corporate purposes.

Cencora, Inc. has entered into an underwriting agreement to issue and sell $1 billion in senior notes due in 2028 and 2032, with the net proceeds intended for general corporate purposes.

Cencora's Q2 2025 revenue reached $75.5 billion, a 10.3% year-over-year increase, with adjusted diluted EPS guidance raised to $15.70-$15.95 for fiscal year 2025.

Cencora, Inc. held its 2025 Annual Meeting of Shareholders on March 6, 2025, where shareholders elected directors, approved executive compensation, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm.

Cencora increases its adjusted diluted earnings per share (EPS) guidance for fiscal year 2025, citing strong performance in its core U.S. Healthcare Solutions segment.

Cencora, Inc. has agreed to repurchase approximately $50 million of its common stock from Walgreens Boots Alliance Holdings LLC in conjunction with Walgreens' sale of Cencora shares under Rule 144.

Cencora's first quarter fiscal year 2025 saw a 12.8% increase in revenue to $81.5 billion and the company raised its adjusted diluted EPS guidance for the full year.